Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- GenesisCare USA - Aventura FP — Aventura, Florida
- GenesisCare USA - Aventura — Aventura, Florida
- Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- Florida Cancer Specialists - Bradenton Cancer Center — Bradenton, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Florida: - Morton Plant Hospital — Clearwater, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- Schulze Family Foundation Cancer Clinic - Bonita Health Center — Bonita Springs, Florida
- Morton Plant Hospital — Clearwater, Florida
- Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Florida: - Halifax Health Cancer Center for Hope - Daytona Beach — Daytona Beach, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Tallahassee Memorial HealthCare — Tallahassee, Florida
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Florida: - Research Site — Clearwater, Florida
- Research Site — Fort Myers, Florida
- Research Site — Gainesville, Florida
- Research Site — Jacksonville, Florida
- Research Site — Orlando, Florida
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Florida: - AdventHealth Altamonte Springs ( Site 0125) — Altamonte Springs, Florida
- Orlando Health Cancer Institute ( Site 0030) — Orlando, Florida
- Comprehensive Hematology Oncology ( Site 0091) — St. Petersburg, Florida
- Cleveland Clinic Martin North Hospital ( Site 0114) — Stuart, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Sites in Florida: - Clinical Trials Site — Jacksonville, Florida
- Clinical Trial Site — Margate, Florida
- Clinical Trial Site — Orlando, Florida
- Clinical Trial Site — Plantation, Florida
- Clinical Trial Site — Tamarac, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Florida: - AdventHealth Altamonte Springs ( Site 0021) — Altamonte Springs, Florida
- University of Florida College of Medicine ( Site 0063) — Gainesville, Florida
- Orlando Health Cancer Institute ( Site 0011) — Orlando, Florida
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Florida: - AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024) — Altamonte Springs, Florida
- Comprehensive Hematology Oncology ( Site 0060) — St. Petersburg, Florida
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in Florida: - Brcr Coral Springs — Coral Springs, Florida
- Florida Clinical Trials Group Plantation — Plantation, Florida
- Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida
- Florida Clinical Trials Group Tamarac — Tamarac, Florida
Phase 3 Recruiting Industry
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Sponsor: AstraZeneca
NCT ID: NCT07205822
Sites in Florida: - Research Site — Largo, Florida
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Broward Health Medical Center — Fort Lauderdale, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Florida: - H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Florida: - Mayo Clinic Florida — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Florida: - Advanced Research LLC — Coral Springs, Florida
- The Oncology Institute of Hope and Innovation — Lakeland, Florida
- D&H Cancer Research Center LLC — Margate, Florida
- HCA Mercy Hospital — Miami, Florida
- BRCR Medical Center Inc. — Plantation, Florida
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Florida: - University of Miami Hospital and Clinics — Miami, Florida
Phase 2 Recruiting NIH
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- UM Sylvester Comprehensive Cancer Center at Kendall — Miami, Florida
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Florida: - Helios CR Inc — Lakeland, Florida
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Florida: - Orlando Health Cancer Institute — Orlando, Florida
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Florida: - Biosresearch Partner — Hialeah, Florida
- D&H Cancer Research Center — Margate, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Florida: - Florida Cancer Specialists & Research Institute — Lake Mary, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Florida: - Florida Cancer Specialists - Lake Nona — Orlando, Florida